Under fire Ranbaxy sold to Sun Pharma for $4 billion
Sun Pharmaceutical Industries has bought struggling drugmaker Ranbaxy Laboratories in a deal that will see the two companies become the biggest in their native India.
Sun has agreed to acquire rival Ranbaxy – which is majority owned by Japan’s Daiichi Sankyo – an all-stock deal worth $4 billion (£2.4 billion)
Under these agreements, Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy.
This exchange represents a premium of 18% to Ranbaxy’s 30-day volume-weighted average share price and a premium of 24.3% to Ranbaxy’s 60-day volume-weighted average share price, in each case, as of the close of business on 4 April.
The combination of Sun Pharma and Ranbaxy creates the fifth-largest specialty generics company in the world, and the largest pharma firm in India.
The combined new company will have operations in 65 countries and 47 manufacturing facilities across five continents.
On a pro forma basis, the combined revenues from the business are estimated at around $4.2 billion, based on last year’s sales.
Sun Pharma says it expects to realise revenue and operating synergies of around $250 million by this year as a result of the deal.
But this comes at a time when Ranbaxy is under intense scrutiny by the FDA, which has imposed import bans on drugs manufactured at a number of its facilities.
In February, the regulator’s commissioner Margaret Hamburg visited India in a quest to shore up quality from all manufacturers there, but the FDA’s crosshairs have been firmly squared on Ranbaxy, which has seen a number of manufacturing issues in the past year.
And in March, the US imposed a ban on imports from a division of Sun Pharma as well, saying that the unit was not “operating in conformity with good manufacturing practices”.
Overall, the FDA has put more than 30 Indian manufacturing units on its ‘import alert’ list, something that can stop products from entering the US.
Ranbaxy’s issues may have made the firm more susceptible to a takeover, but Sun is adamant that despite the company’s problems in the US – and its own – this deal will help it grow.
Dilip Shanghvi, managing director of Sun Pharma, says: “Ranbaxy has a significant presence in the Indian pharma market and in the US where it offers a broad portfolio of ANDAs and first-to-file opportunities. In high-growth emerging markets, it provides a strong platform which is highly complementary to Sun Pharma’s strengths.
“We see tremendous growth opportunities and are excited with the prospects to create lasting value for both our shareholders through a successful combination of our franchises.”
Arun Sahwney, chief executive of Ranbaxy, adds: “We believe this transaction brings significant value to all Ranbaxy shareholders. Sun Pharma has a proven track record of creating significant long-term shareholder value and successfully integrating acquisitions into its growing portfolio of assets.
“We are confident that Sun Pharma is the ideal partner to help us realise our full potential and are excited to participate in future value creation opportunities.”
The proposed transaction has been unanimously approved by the boards of directors of Sun Pharma, Ranbaxy, and Ranbaxy’s controlling shareholder, Daiichi Sankyo.
The pact must now be approved by regulators but Sun Pharma sees the deal being closed by the end of 2014.
Novartis has announced that the US Food and Drug Administration has approved Fabhalta (iptacopan) as …
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca …